Evidence map›Paper›PMID 34906417›Full record

ArticleKidney international2022

KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease.

Vivian Fonseca, Takuji Kohzuma, Rodolfo J Galindo, Cyrus DeSouza

Open access · greenAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Vivian FonsecaMedicine and Pharmacology, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA. Electronic address: vfonseca@tulane.edu.
Takuji KohzumaDiagnostics Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
Rodolfo J GalindoEmory University School of Medicine, Center for Diabetes and Metabolism Research, Emory University Hospital Midtown, Atlanta, Georgia, USA.
Cyrus DeSouzaDivision of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Asahi Kasei (Japan) · JPEmory University Hospital Midtown · USTulane University · USUniversity of Nebraska Medical Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
NIDDK NIH HHS K23 DK123384NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Glycemic ControlRenal Insufficiency, ChronicHumans

Identifiers

PMID34906417
PMCPMC9354805
OpenAlexW4200274796

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.